Low-density lipoprotein receptor mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes

British Journal of Cancer

Volumn 78, Issue 12, 1998, Pages 1607-1614

  Versluis, A J ^a   Rensen, P C N ^a   Rump, E T ^a   Van Berkel, T J C ^a   Bijsterbosch, M K ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Apolipoprotein E; B16 murine melanoma; Drug carrier; Liposomes; Low density lipoprotein receptor; Tumour therapy

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; CALCIUM ION; DAUNORUBICIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; LIPOPHILICITY; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031795075     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.730     Document Type: Article

References (36)

1. Angelin B, Raviola CA, Innerarity TL and Mahley RW (1983) Regulation of hepatic lipoprotein receptors in the dog. J Clin Invest 71: 816-831
2. Bilheimer DW, Eisenberg S and Levy RI (1972) The metabolism of very low density lipoproteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta 280: 212-221
3. Brown MS and Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47
4. De Smidt PC and Van Berkel ThJC (1990) Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res 50: 7476-7482
5. Dietschy JM, Turley SD and Spady DK (1993) Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 34: 1637-1659
6. Firestone RA (1994) Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem 5: 105-113
7. Firestone RA, Pisano JM, Falck JR, McPhaul MM and Krieger M (1984) Selective delivery of cytotoxic compounds to cells by the LDL pathway. J Med Chem 27: 1037-1043
8. Goldstein JL and Brown MS (1974) Binding and degradation of low density lipoproteins by cultured human fibroblasts. J Biol Chem 249: 5153-5162
9. Ho YK, Smith RG, Brown MS and Goldstein JL (1978) Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52: 1099-1114
10. Hynds SA, Welsh J, Stewart JM, Jack A, Soukop M, McArdle CS, Calman KC, Packard CJ and Shepherd J (1984) Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim Biophys Acta 795: 589-595
11. Innerarity TL and Mahley RW (1978) Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 17: 1440-1447
12. Innerarity TL, Pitas RE and Mahley RW (1479) Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem 254: 4186-4190
13. Isaacsohn JL, Lees AM, Lees RS, Strauss HW, Barlai-Kovach M and Moore TJ (1986) Adrenal imaging with technetium-99m-labelled low density lipoproteins. Metabolism 35: 364-366
14. Kleinherenbrink-Stins MF, Van Der Boom J, Bakkeren HF, Roholl PJM, Brouwer A, Van Berkel ThJC and Knook DL (1990) Light- and immunoelectron microscopic visualization of in vivo endocytosis of low density lipoprotein by hepatocytes and Kupffer cells in rat liver. Lab Invest 63: 73-86
15. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275
16. Lundberg B and Suominen L (1984) Preparation of biologically active analogs of serum low density lipoprotein. J Lipid Res 25: 550-558
17. Lundberg B, Hong K and Papahadjopoulos D (1993) Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. Biochim Biophys Acta 1149: 305-312
18. Masquelier M, Vitols S and Peterson C (1986) Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug human low-density lipoprotein complexes in mice. Cancer Res 46: 3842-3847
19. Mosley ST, Goldstein JL, Brown MS, Falck JR and Anderson RGW (1981) Targeted killing of cultured cells by receptor-dependent photosensitization. Proc Natl Acad Sci USA 78: 5717-5721
20. Murray JC and Carmichael J (1995) Targeting solid tumours: challenges, disappointments and opportunities. Adv Drug Deliv Rev 17: 117-127
21. Packard CJ, McKinncy L, Carr K and Shepherd J (1983) Cholesterol feeding increases low density lipoprotein synthesis. J Clin Invest 72: 45-51
22. Pitas RE, Innerarity TL, Arnold KS and Mahley RW (1979) Rate and equilibrium constants for binding of apo-E HDL (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDL. Proc Natl Acad Sci USA 76: 2311-2315
23. Pitas RE, Innerarity TL and Mahley RW (1980) Cell surface receptor binding of phospholipid protein complexes containing different ratios of receptor-active and -inactive E apolipoprotein. J Biol Chem 255: 5454-5460
24. Pittman RC, Carew TE, Glass CK, Green SR, Taylor CA and Attie AD (1983) A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J 212: 791-800
25. 99mTc-labelled LDL in B16-melanoma-bearing mice. Visualization of a preferential uptake by the tumor. Int J Cancer 54: 411-417
26. Redgrave TG, Roberts DCK and West CE (1975) Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 65: 42-49
27. Rensen PCN, Schiffelers RM, Versluis AJ, Bijsterbosch MK, Meuwissen MEMJ and Van Berkel ThJC (1997) Human recombinant apolipoprotein E-enriched liposomes can mimic low density lipoproteins as carriers for the site-specific delivery of anti-tumor agents. Mol Pharmacol 52: 445-455
28. Samadi-Baboli M, Favre G, Bernadou J, Berg D and Soula G (1990) Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug-LDL complex via the LDL receptor pathway in vitro. Biochem Pharmacol 40: 203-212
29. Samadi-Baboli M, Favre G, Canal P and Soula G (1993) Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. Br J Cancer 68: 319-326
30. Speth PAJ, Van Hoesel QGCM and Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15: 15-31
31. Tokui T, Tokui Y, Ishigami M, Tanzawa K, Ikeda T and Komai T (1994) Targeting of an antitumor agent, RS-1541 (palmitoyl-rhizoxin), via low-density lipoprotein receptor. Int J Pharm 110: 277-283
32. Van Berkel ThJC, Kruijt JK, Van Gent T and Van Tol A (1981) Saturable high affinity binding, uptake and degradation of rat plasma lipoproteins by isolated parenchymal and non-parenchymal cells from rat liver. Biochem Biophys Acta 665: 22-33
33. Versluis AJ, Van Geel PJ, Oppelaar H, Van Berkel ThJC and Bijsterbosch MK (1996) Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br J Cancer 74: 525-532
34. Versluis AJ, Rump ET, Rensen PCN, Van Berkel ThJC and Bijsterbosch MK (1998) Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. Pharm Res 15: 531-537
35. Vitols SG, Masquelier M and Peterson CO (1985) Selective uptake of a toxic lipophilic anthracycline derivative by the LDL receptor pathway in cultured fibroblasts. J Med Chem 28: 451-454
36. Vogel T, Weisgraber KH, Zeevi MI, Ben-Artzi HB, Levanon AZ, Rall Jr. SC, Innerarity TL, Hui DY, Taylor JM, Kanner D, Yavin Z, Amit B, Aviv H, Gorecki M and Mahley RW (1985). Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. Proc Natl Acad Sci USA 82: 8696-8700